BioLineRx Upgraded by StockNews.com to Hold - Defense World
| BLRX Stock | ILS 8.10 0.10 1.25% |
About 62% of BioLine RX's investor base is looking to short. The analysis of current outlook of investing in BioLine RX suggests that many traders are alarmed regarding BioLine RX's prospects. The current market sentiment, together with BioLine RX's historical and current headlines, can help investors time the market. In addition, many technical investors use BioLine RX stock news signals to limit their universe of possible portfolio assets.
BioLine |
BioLineRx Upgraded by StockNews.com to Hold Defense World
Read at news.google.com
 |
BioLine RX Fundamental Analysis
We analyze BioLine RX's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLine RX using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLine RX based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
BioLine RX is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
BioLine RX Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioLine RX stock to make a market-neutral strategy. Peer analysis of BioLine RX could also be used in its relative valuation, which is a method of valuing BioLine RX by comparing valuation metrics with similar companies.
Peers
BioLine RX Related Equities
| ILDR | Israel Land | 7.58 | ||||
| BEZQ | Bezeq Israeli | 0.75 | ||||
| MVNE | Mivne Real | 0.56 | ||||
| PHTM | Photomyne | 0.07 | ||||
| BRIN | Brainsway | 1.89 |
Complementary Tools for BioLine Stock analysis
When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |